West Lake Dermatology

MARCH 25, 2024

Seborrheic Dermatitis (SD) is common skin condition known for its chronic and recurrent nature. Understanding seborrheic dermatitis is the first step towards managing it effectively. By recognizing the symptoms and causes, you can take steps to prevent flare-ups and find the right treatment for you.

Dermatitis 36

Dermatitis Treatments Management Eczema 36

Dermatology Times

APRIL 12, 2024

Linda Stein-Gold, MD, and Michael Cameron, MD, FAAD, discuss the need for non-steroidal treatment options in atopic dermatitis management, driven by patient preferences.

Dermatitis 69

Dermatitis Treatments Irritation Management 69

Dermatology Times

JUNE 27, 2024

A dermatology expert reviews findings from a recently presented study on using other atopic dermatitis (AD) treatments within six months of initiating ruxolitinib cream.

Dermatitis 36

Dermatitis Management Treatments Dermatology 36

Dermatology Times

AUGUST 27, 2024

The AHEAD recommendations focus on achieving disease control in atopic dermatitis by allowing patients to identify key symptoms and clinicians to select matching outcomes to guide therapy, aiming for a higher standard of care.

Dermatitis 45

Dermatitis Treatments Therapy 45

Dermatology Times

OCTOBER 31, 2024

Egeberg discusses promising new treatments and insights from recent clinical trials, highlighting significant advancements in chronic hand eczema and atopic dermatitis care presented at the EADV 2024.

Eczema 74

Eczema Dermatitis Clinic Treatments 74

First Derm

APRIL 5, 2024

Factors affecting adherence include socioeconomic status, treatment complexity, and the specific skin condition being treated. Strategies to improve adherence range from using eHealth tools and educational resources to simplifying treatment regimens.

Dermatology 59

Dermatology Treatments Education Medical 59

Dermatology Times

JUNE 13, 2024

An expert in the management of dermatological conditions shares insights on managing atopic dermatitis patients, discussing the real-world effectiveness and physician satisfaction with ruxolitinib cream as a treatment option, as well as its adoption among healthcare providers.

Dermatitis 36

Dermatitis Management Treatments Clinic 36

The Dermatology Digest

APRIL 7, 2024

A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). Nonsteroidal treatment options for AD have rapidly expanded in recent years with the development of phosphodiesterase-4 inhibitors, biologics, and Janus kinase (JAK) inhibitors.

Treatments 77

Treatments Dermatitis Therapy Medical 77

Dermatology Times

DECEMBER 20, 2023

Tapinarof is showing promise in the landscape of dermatological treatment. Adelaide Hebert, MD, FAAD, recently served as an investigator for 2 studies presented at the European Academy of Dermatology and Venereology (EADV) Congress and discussed key points with Raj Chovatiya, MD, PhD.

Treatments 73

Treatments Dermatitis Dermatology 73

The Dermatology Digest

SEPTEMBER 14, 2023

Daniel Butler discusses strategies for diagnosing atypical dermatitis and overcoming medication access issues, including the use of alternative metrics to measure disease severity, practicing physician patience, and learning to navigate the payer system. We are so reliant on our physical exam skills [and] appropriately so.

Dermatitis 48

Dermatitis Treatments Medical Office 48

Dermatology Times

OCTOBER 3, 2024

Jason Hawkes, MD, MS, emphasized the importance of biologic treatments transforming the management of both prurigo nodularis and atopic dermatitis.

Dermatitis 74

Dermatitis Clinic Management Treatments 74

The Dermatology Digest

JANUARY 22, 2024

s ZORYVE topical foam, 0.3%, is now officially available for the treatment of seborrheic dermatitis. Food and Drug Administration (FDA) approved ZORYVE foam for the treatment of seborrheic dermatitis in individuals 9 years of age and older on December 15, 2023. appeared first on The Dermatology Digest.

Dermatitis 78

Dermatitis Treatments Innovations Clinic 78

Dermatology Times

OCTOBER 3, 2023

Experts in dermatology discuss their considerations for atopic dermatitis and plaque psoriasis topical treatment options highlighting the different penetration, access, and safety considerations.

Dermatitis 36

Dermatitis Treatments Safety Dermatology 36

Dermatology Times

APRIL 5, 2024

Mark Lebwohl, MD, emphasizes the importance of considering various factors, including severity of itch and interference with sleep, when determining treatments for patients with atopic dermatitis, even with presentation may not include typical symptoms.

Dermatitis 87

Dermatitis Treatments 87

Dermatology Times

JUNE 26, 2024

Focusing on pregnant patients with atopic dermatitis who are treatment naïve, Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, discuss best practices for informing patients on the available treatment options for this condition.

Dermatitis 36

Dermatitis Treatments 36

Dermatology Times

DECEMBER 18, 2023

Raj Chovatiya, MD, PhD introduces a video series program exploring cutting-edge treatments at the forefront of atopic dermatitis management, exploring innovative insights and research that will redefine dermatological care.

Dermatitis 36

Dermatitis Dermatology Innovations Management 36

First Derm

FEBRUARY 21, 2024

Treatment Approaches Vary : Treatment for eczema includes emollients and topical steroids, while psoriasis may be treated with light therapy, systemic medications, and biologics, emphasizing the need for personalized care. Contact dermatitis from metals, latex, chemicals. 2] Why is Eczema Considered a Chronic Condition?

Eczema 59

Eczema Dermatitis Management Medical 59

Dermatology Times

SEPTEMBER 3, 2024

The TARGET-DERM registry longitudinal study highlighted the continued trend of the failure to escalate atopic dermatitis treatments when patients do not meet their therapeutic targets.

Treatments 69

Treatments Dermatitis 69

The Dermatology Digest

FEBRUARY 8, 2024

The Dermatology Digest asked key thought leaders and editorial advisory board members to take out their crystal balls and weigh in on what’s to come in 2024 and beyond. Inside the Burgeoning AD Pipeline AD is another dermatologic condition that is undergoing a transformation in terms of treatment options and paradigms.

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

Dermatology Times

MAY 7, 2024

A 5-expert panel delves into atopic dermatitis guidelines and recommendations and recent studies to make note of.

Dermatitis 88

Dermatitis Clinic Treatments 88

Dermatology Times

JULY 2, 2024

A medical expert in dermatology examines comprehensive treatment approaches for atopic dermatitis in a 12-year-old African American female patient, focusing on the assessment of topical and non-steroidal therapeutic options.

Dermatitis 36

Dermatitis Treatments Medical Dermatology 36

First Derm

OCTOBER 14, 2023

Online Dermatologist Cannabinoids for the Treatment of Dermatologic Conditions Psychoactive Components | Cannabinoid Use in Dermatology | Classes of Cannabinoids | Cannabinoids for skin conditions The field of dermatology has witnessed a remarkable evolution in recent years, with the integration of cannabinoids into treatment regimens.

Dermatology 40

Dermatology Treatments Dermatitis Innovations 40

Dermatology Times

JANUARY 25, 2024

Patients with moderate to severe AD gave their opinions in a survey on treatment options and their tradeoffs. Itch control topped the list of patient concerns.

Treatments 78

Treatments Dermatitis 78

Dermatology Times

JULY 3, 2024

Drs Kiracofe and Murase provide clinical insights on treatment escalation practices for patients with atopic dermatitis who are pregnant.

Dermatitis 36

Dermatitis Treatments Management Clinic 36

Dermatology Times

APRIL 19, 2024

Michael Cameron, MD, identifies the most important pearls from the latest atopic dermatitis treatment guidelines set forth by the American Academy of Dermatology.

Dermatitis 36

Dermatitis Dermatology Treatments 36

The Dermatology Digest

OCTOBER 8, 2024

April Armstrong, MD, Professor and Chief of Dermatology at University of California-Los Angeles (UCLA), shares interim results from the TRACE study. at nine months of treatment with tralokinumab (Adbry/Adtralza, Leo), regardless of previous biologic treatment. at baseline to 33.6% at three months, 48.4% at six months, and 57.4%

Dermatitis 74

Dermatitis Dermatology Treatments 74

Dermatology Times

FEBRUARY 9, 2024

A discussion among roundtable participants revolved around the importance of effective communication, the impact of prolonged use of topical steroids, and the need for trust building in recommending novel treatment options.

Treatments 78

Treatments Dermatitis 78

Dermatology Times

JULY 10, 2024

Looking to the future of atopic dermatitis treatment, Drs Kiracofe and Murase offer concluding remarks on current unmet needs, the benefits of treatment guidelines, and the importance of treating itch in patients who are or may become pregnant.

Dermatitis 36

Dermatitis Treatments 36

MedEsthetics

AUGUST 11, 2023

atopic dermatitis, acne, inflammatory conditions, skincare, acne treatment, peptide, medical aesthetics, clinical trials, phase 1 study, British journal of dermatology

Dermatitis 60

Dermatitis Skincare Clinic Medical 60

Dermatology Times

MAY 21, 2024

A 5-expert panel continues their conversation on atopic dermatitis, discussing patient-centered care and key takeaways.

Dermatitis 74

Dermatitis Clinic Treatments 74

Dermatology Times

MAY 14, 2024

A 5-expert panel continues their conversation on atopic dermatitis, exploring beyond steroids and addressing unmet needs.

Dermatitis 74

Dermatitis Clinic Treatments 74

Dermatology Times

MAY 6, 2024

Elizabeth Kiracofe, MD, provides a look at an upcoming DermView program that will explore systemic treatments for atopic dermatitis in the context of reproductive health, for patients during pregnancy, pre-pregnancy, postpartum, and breastfeeding.

Dermatitis 36

Dermatitis Safety Treatments 36

The Dermatology Digest

OCTOBER 29, 2024

Linda Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, MI, reviews new data on atopic dermatitis (AD) patients who switched to lebrikizumab (Ebyglyss, Lilly) from dupilumab (Dupixent, Sanofi and Regeneron) that was presented at the 2024 Fall Clinical Dermatology Conference in Las Vegas, NV. “If

Dermatitis 74

Dermatitis Dermatology Clinic Treatments 74

The Dermatology Digest

OCTOBER 26, 2024

Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. Both groups had similar proportions of patients with treatment-emergent adverse events (TEAEs).

Dermatitis 36

Dermatitis Treatments Pharmaceutical Eczema 36

Dermatology Times

JULY 3, 2024

Experts on atopic dermatitis weigh the risks and rewards of systemic treatments for pregnant patients and provide clinical insights on monitoring for adverse effects associated with dupilumab.

Dermatitis 36

Dermatitis Treatments Clinic 36

Dermatology Times

JANUARY 11, 2024

Innovative practice pearls for both vitiligo and atopic dermatitis treatment were shared with nearly 200 clinicians to put into practice at the virtual Revolutionizing Vitiligo and Revolutionizing Atopic Dermatitis Conferences.

Dermatitis 74

Dermatitis Innovations Treatments 74

Dermatology Times

DECEMBER 12, 2023

The poster was presented at the 2023 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference.

Dermatitis 74

Dermatitis Treatments 74